GlassScriptPhysician profile
Roland Espeleta Abundo
NPI 1013970235
$9,316.46
in general payments reported to CMS, 2019-2025
28 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $575 · 2021: $1,862 · 2022: $1,470 · 2023: $1,148 · 2024: $1,227 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,877 · Entertainment: $76.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.33 |
| Entertainment | $76.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,016.80 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,051.53 | 2019-2021 | |
| Coopervision INC. | $846.65 | 2019-2025 | Myday Contact Lens, Onefit Contact Lens, Clariti Contact Lens |
| Allergan, INC. | $821.00 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $778.72 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $752.01 | 2021-2024 | Eysuvis, Precision 1, Precision 7 |
| Sun Pharmaceutical Industries INC. | $493.57 | 2020-2025 | |
| Oyster Point Pharma, INC. | $361.54 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $341.58 | 2021-2022 | |
| Optos, INC. | $244.22 | 2021-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abb Con-Cise Optical Group LLC | $162.70 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $151.82 | 2023-2025 | Lipiflow System Activator (Disposable) |
| Novartis Pharmaceuticals Corporation | $147.77 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $143.30 | 2025 | Xdemvy |
| Glaukos Corporation | $133.95 | 2025 | Photrexa Viscous and Photrexa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $125.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $123.19 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $122.58 | 2021 | |
| Lkc Technologies, INC. | $91.94 | 2025 | |
| Horizon Therapeutics Plc | $90.61 | 2023 | Tepezza |
| Abbvie INC. | $68.34 | 2024 | |
| Biotissue Holdings INC. | $63.54 | 2021-2024 | |
| Hoffmann-La Roche Limited | $46.20 | 2019 | |
| Heru, INC. | $40.94 | 2022 | |
| Thea Pharma INC. | $36.32 | 2024-2025 | Iyuzeh |
| Sight Sciences, INC. | $24.84 | 2022 | |
| Dompe US, INC. | $18.60 | 2024 | Oxervate |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roland Abundo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.